Belgium's UCB Pharma hit with FDA Form 483 after April inspection
UCB Pharma, a Belgium-based biopharma company, has been slapped with a Form 483 from the FDA following an inspection that uncovered issues with its quality control unit and product storage.
UCB Pharma | 31/05/2023 | By Sudeep Soparkar | 461
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy